Menu
Back to Journals » OncoTargets and Therapy » Volume 7
Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era
Authors Berger J, Smith A, Zorn K, Sukumvanich P, Olawaiye A, Kelley J, Krivak T
Received 22 February 2014
Accepted for publication 7 April 2014
Published 8 August 2014 Volume 2014:7 Pages 1409—1413
DOI https://doi.org/10.2147/OTT.S62881
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Jessica L Berger, Ashlee Smith, Kristin K Zorn, Paniti Sukumvanich, Alexander B Olawaiye, Joseph Kelley, Thomas C Krivak
Magee-Womens Hospital, University of Pittsburgh Medical Center, Division of Gynecologic Oncology, Pittsburgh, PA, USA
Corrigendum for this paper has been published
A Letter to the Editor has been received and published for this article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.